ⅠB2-ⅡB期宫颈癌新辅助治疗联合手术对比根治性同步放化疗疗效及安全性的Meta分析

doi:10.3760/cma.j.issn.1004-4221.2019.06.007

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To systematically evaluate the efficacy and safety between neoadjuvant therapy followed by radical surgery and definite chemoradiotherapy in the treatment of ⅠB2-ⅡB cervical cancer.Methods A computerized search was performed in PubMed, Embase, Cochrane Library, Web of Science, CBM, Wanfang Data, CNKI and VIP to collect controlled clinical trials related to neoadjuvant therapy followed by radical surgery versus definite chemoradiotherapy in the treatment of ⅠB2-ⅡB cervical cancer. The meta-analysis of survival data and adverse events was performed by Review Manager 5.3 software.Results Nine controlled clinical trials involving 3 914 patients were included in this meta-analysis. There were no significant differences in overall survival (HR=0.83, P=0.31) and progression-free survival (HR=0.85,P=0.57) between two groups. Compared with patients receiving definite chemoradiotherapy, those in the neoadjuvant therapy group had a significantly lower risk of irradiation enteritis (RR=0.27,P=0.03), whereas no significant difference was observed in the risk of irradiation cystitis (RR=0.30,P=0.34) and grade ≥3 neutropenia (RR=0.77,P=0.46) between two groups. Conclusion In the treatment of locally advancedⅠB2-ⅡB cervical cancer, two modalities show similar survival benefits. Although the neoadjuvant therapy group yields a lower incidence of irradiation enteritis, the incidence rates of irradiation cystitis and grade ≥3 neutropenia do not significantly differ between two groups. Neoadjuvant therapy followed by radical surgery is not superior to the standard therapeutic regime.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Key words： Cervical neoplasm/surgery Cervical neoplasm/concurrent radiochemotherapy Prognosis Meta-analysis

Received: 16 September 2018

Fund:“Six One Project” of High-level Medical Talents in Jiangsu Province (LGY2016041)

Corresponding Authors: Yao Yuanhu,Email:yyhxz@xzhmu.edu.cn

Cite this article:

. The efficacy and safety of neoadjuvant therapy followed by radical surgery versus definite chemoradiotherapy in the treatment of ⅠB2-ⅡB cervical cancer:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2019, 28(6): 428-431.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2019.06.007 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2019/V28/I6/428

[1] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012[J].Cancer J Clin,2015,65(2):87-108.DOI:10.3322/caac.21262.
[2] Kokka F,Bryant A,Brockbank E,et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer[J].Cochrane Data Syst Rev,2015,4:CD010260.DOI:10.1002/14651858.CD010260.pub2.
[3] Morris M,Eifel PJ,Lu J,et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J].New Engl J Med,1999,340(15):1137-1143.DOI:10.1056/NEJM199904153401501.
[4] Keys HM,Bundy BN,Stehman FB,et al. Cisplatin,radiation,and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage ⅠB cervical carcinoma[J].New Engl J Med,1999,340(15):1154-1161.DOI:10.1056/NEJM199904153401503.
[5] Rose PG,Bundy BN,Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J].New Engl J Med,1999,340(15):1144-1153.DOI:10.1056/NEJM199904153401502.
[6] Whitney CW,Sause W,Bundy BN,et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ⅡB-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes:a Gynecologic Oncology Group and Southwest Oncology Group study[J].J Clin Oncol,1999,17(5):1339-1348.DOI:10.1200/JCO.1999.17.5.1339.
[7] Peters WA,3rd,Liu PY,Barrett RJ,2nd,et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J].J Clin Oncol,2000,18(8):1606-1613.DOI:10.1200/JCO.2000.18.8.1606.
[8] Vale C,Tierney JF,Stewart LA,et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer:a systematic review and meta-analysis of individual patient data from 18 randomized trials[J].J Clin Oncol,2008,26(35):5802-5812.DOI:10.1200/JCO.2008.16.4368.
[9] Gong L,Lou JY,Wang P,et al. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage ⅠB2-ⅡB cervical cancer[J].Int J Gynaecol Obstet,2012,117(1):23-26.DOI:10.1016/j.ijgo.2011.11.017.
[10] Rydzewska L,Tierney J,Vale CL,et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J].The Cochrane database of systematic reviews,2012,12:CD007406.DOI:10.1002/14651858.CD007406.pub3.
[11] Eddy GL,Bundy BN,Creasman WT,et al. Treatment of ("bulky") stage ⅠB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy:a phase Ⅲ trial of the gynecologic oncology group[J].Gynecol oncol,2007,106(2):362-369.DOI:10.1016/j.ygyno.2007.04.007.
[12] Cetina L,Gonzalez-Enciso A,Cantu D,et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin:a randomized,phase Ⅲ study in ⅠB2-ⅡB cervical cancer patients[J].Ann Oncol,2013,24(8):2043-2047.DOI:10.1093/annonc/mdt142.
[13] Gupta S,Maheshwari A,Parab P,et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage ⅠB2,ⅡA,or ⅡB squamous cervical cancer:a randomized controlled trial[J].J Clin Oncol,2018,36(16):1548-1555.DOI:10.1200/JCO.2017.75.9985.
[14] 陈锡山,邹文,杜祯,等.同步放化疗与新辅助化疗联合手术加辅助放疗治疗Ⅱ b期宫颈癌的对比分析[J].现代肿瘤医学,2017,15:2467-2471.DOI:10.3969/j.issn.1672-4992.2017.15.031.
Chen XS,Zou W,Du Z,et al. Comparative analysis of synchronous radiotherapy and chemotherapy combined with neoadjuvant chemotherapy in the treatment of cervical cancer in the Ⅱ b period[J].Mod Oncol Med,2017,15:2467-2471.DOI:10.3969/j.issn.1672-4992.2017.15.031.
[15] Wang N,Li WW,Li JP,et al. Comparison of concurrent chemoradiotherapy followed by radical surgery and high-dose-rate intracavitary brachytherapy:a retrospective study of 240 patients with FIGO stage ⅡB cervical carcinoma[J].OncoTarget Ther,2014,7:91-100.DOI:10.2147/OTT.S52710.
[16] Guo L,Liu X,Wang L,et al. Outcome of international Federation of gynecology and obstetrics stage Ⅱ b cervical cancer from 2003 to 2012:an evaluation of treatments and prognosis:a retrospective study[J].Int J Gynecol Cancer Soc,2015,25(5):910-918.DOI:10.1097/IGC.0000000000000430.
[17] Yin M,Zhao F,Lou G,et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer[J].Int J Gynecol Cancer Soc,2011,21(1):92-99.DOI:10.1111/IGC.0b013e3181fe8b6e.
[18] Hsieh HY,Huang JW,Lu CH,et al. Definite chemoradiotherapy is a competent treatment option in FIGO stage ⅠB2 cervical cancer compared with radical surgery+/-neoadjuvant chemotherapy[J].J Form Med Associat,2018,pii:S0929-6646(17)30732-30735.DOI:10.1016/j.jfma.2018.01.015.
[19] Chereau E,C DLH,Ballester M,et al. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-ⅡB cervical cancer[J].Anticancer research,2013,33(4):1661-1666.
[20] Haque W,Verma V,Butler EB,et al. Utilization of hysterectomy following chemoradiation for ⅠB2/ⅡA2 cervical cancer in the national cancer data base[J].Anticancer Res,2018,38(5):3175-3179.DOI:10.21873/anticanres.12581.